Maccura Biotechnology (300463.SZ): Obtained product registration certificates for two new products.
Maccura Biotechnology (300463.SZ) announced on August 13th that the company has recently received the Medical Device Registration Certificate (In Vitro Diagnostic Reagents) issued by the National Medical Products Administration. The products that have obtained product registration certificates are cytomegalovirus IgM antibody detection reagent kit (direct chemiluminescence method) and herpes simplex virus type 2 IgM antibody detection test kit (direct chemiluminescence method). Cytomegalovirus IgG antibody detection reagent kit (direct chemiluminescence method), as a pathogen antibody detection test kit, is currently mainly used for auxiliary diagnosis of cytomegalovirus infection. Herpes simplex virus type 2 IgM antibody detection test.
We Think Maccura BiotechnologyLtd (SZSE:300463) Can Stay On Top Of Its Debt
Maccura Biotechnology: Half-year report for the year 2024.
Maccura Biotechnology: Summary of Half-Year Report in 2024.
Maccura Biotechnology (300463.SZ) has repurchased 0.48% of its shares in total.
Maccura Biotechnology (300463.SZ) announced that as of July 31, 2024, the company has accumulated the repurchase of 2,954,300 shares of the company through a repurchase special securities account, using centralized competitive trading. The proportion of the current total share capital of the company is 0.48%, with a fill price of 12.13 yuan/share, a highest trade of 13.23 yuan/share, a lowest trade of 10.91 yuan/share and a total payment of 35,828,060.82 yuan (excluding transaction fees). The repurchase complies with the company's share repurchase plan and relevant laws and regulations.
Maccura Biotechnology (300463.SZ) has obtained two medical instrument registration certificates.
Maccura Biotechnology (300463.SZ) announced that the company recently received approval from the National Medical Products Administration and the Sichuan Provincial Drug Administration...
As of January 10th, the number of shareholders in Maccura Biotechnology (300463.SZ) was 39,558.
Maccura Biotechnology (300463.SZ) stated on the investor interaction platform on July 19th that as of the close on January 10th, 2024, the number of shareholders in the company was 39,558.
Maccura Biotechnology (300463.SZ): Cumulatively repurchased 0.29% of shares.
Maccura Biotechnology (300463.SZ) announced that as of June 30, 2024, the company has repurchased 1,796,900 shares of the company through a buyback special securities account by centralized auction trading, accounting for 0.29% of the current total share capital of the company, with a average fill price of 12.72 yuan/share, the highest fill price of 13.23 yuan/share, the lowest fill price of 12.18 yuan/share, and the total amount paid excluding transaction costs was 22,859,248.82 yuan. This buyback is in compliance with the company's share repurchase plan and relevant laws and regulations.
Maccura Biotechnology (300463.SZ) annual equity distribution in 2023: each 10 shares will be distributed 1.540240 yuan. The registration date of stock rights is July 2nd.
Maccura Biotechnology (300463.SZ) announced its annual equity distribution plan for 2023: based on the company's current...
A Piece Of The Puzzle Missing From Maccura Biotechnology Co.Ltd's (SZSE:300463) Share Price
Maccura Biotechnology (300463.SZ) obtained a medical instrument registration certificate.
Maccura Biotechnology (300463.SZ) announced that the company recently received the "Medical instrument..." issued by the National Medical Products Administration.
Maccura Biotechnology Gets Nod to Register Automatic Biochemical Analyzer
Subsidiary of Maccura Biotechnology (300463.SZ) obtained a medical instrument registration certificate.
Maccura Biotechnology (stock code 300463.SZ) announced that its wholly-owned subsidiary Maccura Medical Electronics Co., Ltd. recently received four...
Maccura Biotechnology (300463.SZ): Fully Automated Biochemical Analyser Obtains Product Registration Certificate.
Maccura Biotechnology (300463.SZ) announced on June 20 that its wholly-owned subsidiary, Maccura Medical Electronics Co., Ltd., recently received a "Medical Device Registration Certificate" issued by the Sichuan Provincial Drug Administration for a fully automatic biochemical analyzer. The fully automatic biochemical analyzer has achieved breakthroughs in multiple core technologies such as optical system and ultrasonic mixing system, ensuring excellent product performance; intelligent functions such as online non-stop loading and automatic maintenance provide customers with more convenient operation experience; precision manufacturing combined with stable running system and internationally leading value traceability capability ensures laboratory testing results with accuracy and reliability.
Maccura Biotechnology (300463.SZ) granted 7.3029 million restricted stocks.
Maccura Biotechnology (300463.SZ) announced that the board of directors of the company believes that the grant conditions stipulated in the company's 2024 restricted stock incentive plan have been achieved. According to the authorization of the company's first extraordinary shareholders' meeting in 2024, June 6, 2024, is approved as the first grant date, and 7.3029 million restricted stocks will be granted to 117 incentive objects who meet the grant conditions.
Maccura Biotechnology (300463.SZ) has cumulatively spent 22.859 million yuan to repurchase 0.29% of its shares.
On June 4th, Gelon Hui reported that as of May 31, 2024, Maccura Biotechnology (300463.SZ) had repurchased a total of 1,796,900 shares of the company through a repurchase special securities account in a centralized bidding transaction, accounting for 0.29% of the company's current total share capital. The average transaction price was 12.72 yuan/share, the highest transaction price was 13.23 yuan/share, the lowest transaction price was 12.18 yuan/share, and the total amount paid was 22,859,248.82 yuan (excluding transaction fees).
Individual Investors Among Maccura Biotechnology Co.Ltd's (SZSE:300463) Largest Stockholders and Were Hit After Last Week's 6.5% Price Drop
Mike Biotech (300463.SZ) plans to launch the 2024 Restricted Stock Incentive Plan
Mike Biotech (300463.SZ) released the 2024 Restricted Stock Incentive Plan (Draft) to be awarded...
Maccura BiotechnologyLtd's (SZSE:300463) Soft Earnings Are Actually Better Than They Appear
Mike Biotech (300463.SZ): Net profit of 120 million yuan in the first quarter increased by 3.05% year-on-year
On April 24, GLONGHUI (300463.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 616 million yuan, down 8.88% year on year; net profit attributable to shareholders of listed companies was 120 million yuan, up 3.05% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 118 million yuan, down 2.00% year on year; basic earnings per share were 0.20 yuan.
No Data